跳至主要内容

Obesity Found to Have Distinct Neural Pathway

 Obesity means having too much body fat. It is different from being overweight, which means weighing too much. The weight may come from muscle, bone, fat, and/or body water. Both terms mean that a person’s weight is greater than what’s considered healthy for his or her height.

Researchers at The Rockefeller University report that two populations of cells in the brain may be responsible for regulating appetite. They published their findings (“Identification of a Brainstem Circuit Controlling Feeding”) in Cell.

The two types of cells, located in the dorsal raphe nucleus (DRN), are potential targets for new drugs to treat obesity by controlling the hunger signals that drive the search for and consumption of food.

In the field of metabolic diseases, we are proud of our portfolio of stable and effective animal models, especially those for Non-alcoholic Fatty Liver Disease (NAFLD). Though popular recently, they still lack effective drug treatment.

“…we show that neurons in the dorsal raphe nucleus, expressing vesicular transporters for GABA [gamma-aminobutyric acid] or glutamate (hereafter, DRNVgat and DRNVGLUT3 neurons), are reciprocally activated by changes in energy balance and that modulating their activity has opposite effects on feeding—DRNVgat neurons increase, whereas DRNVGLUT3 neurons suppress, food intake,” write the investigators. “Furthermore, modulation of these neurons in obese (ob/ob) mice suppresses food intake and body weight and normalizes locomotor activity.

“Finally, using molecular profiling, we identify druggable targets in these neurons and show that local infusion of agonists for specific receptors on these neurons has potent effects on feeding. These data establish the DRN as an important node controlling energy balance.”

“Obesity is generally associated with leptin resistance,” says Jeffrey Friedman, M.D., Ph.D., Marilyn M. Simpson Professor and head of Rockefeller’s laboratory of molecular genetics. “And our recent data suggest that modulation of the activity of specific neurons with drugs could bypass leptin resistance and provide a new means for reducing body weight.”

Alexander Nectow, who completed his Ph.D. in Dr. Friedman’s lab, and colleagues focused on the DRN when whole-brain imaging made with iDISCO, an advanced technique developed at Rockefeller, revealed that this part of the brain becomes activated in hungry mice. Subsequent imaging of other mice that were fed more than their normal amount of food, until they were full, revealed a different pattern of DRN activity.

These results indicated quite clearly that neurons in that part of the brain played a role in feeding behavior, say the scientists.

The next step, explains Dr. Nectow, now an associate research scholar at Princeton University, was to determine which of the several types of neurons that make up the DRN were involved. Genetic analysis of the activated cells in the two groups of mice showed that the neurons triggered by mice who had eaten released glutamate, a chemical that nerve cells use to signal one another, while the neurons triggered by hunger released a different neurotransmitter, known as GABA.

“There are two possibilities when you see something like that,” Dr. Nectow says. “One is that the cells are just along for the ride—they are getting activated by hunger but they’re not actually driving the food intake process. The other possibility is that they are in fact part of the sense and respond mechanism to hunger—and in this case, we suspected the latter.”

The researchers turned on the glutamate-releasing cells in obese mice. This suppressed the animals’ food intake and made them lose weight. And it confirmed that the DRN neurons turned on by hunger did indeed drive food intake.

Turning on the GABA-releasing neurons in the same part of the brain had the opposite effect and increased food intake. Notably, activating the “hunger neurons” automatically turned off the “satiety neurons,” maximizing the effect.

The researchers next looked at what would happen if they switched off hunger neurons in obese mice. “We were excited to see that prolonged inhibition of these neurons could dramatically reduce body weight,” says postdoctoral fellow Marc Schneeberger Pane, Ph.D.

The findings open up new avenues of research into exactly how the brain controls eating and suggest that drugs designed to activate or inhibit neurons in the DRN could be effective in treating obesity and preventing its related disorders, such as diabetes and hypertension.

评论

此博客中的热门博文

What is preclinical testing?

In the process of  preclinical testing  of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a  preclinical research  phase followed, before which, as described above, the potential toxicity of the compou

Inventory of the three major in vitro pharmacokinetic research methods

  The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d

Novel Parkinson’s Therapies Possible with New Mouse Model

Parkinson's disease (PD) is a neurodegenerative disorder that is marked by the accumulation of the protein, α-synuclein (αS), into clumps known as Lewy bodies, which diminish neural health. Now, researchers from Brigham and Women's Hospital (BWH) report the development of a mouse model to induce PD-like αS aggregation, leading to resting tremor and abnormal movement control. The mouse responds to L-DOPA, similarly to patients with PD. The team's study (“Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson’s Disease”) on the use of this transgenic mouse model appears in  Neuron . “α-Synuclein (αS) regulates vesicle exocytosis but forms insoluble deposits in PD. Developing disease-modifying therapies requires animal models that reproduce cardinal features of PD. We recently described a previously unrecognized physiological form of αS, α-helical tetramers, and showed that familial PD-causing missense mutati